- 专利标题： Nanoparticulate formulation comprising a TRPA1 antagonist
-
申请号： US14310447申请日： 2014-06-20
-
公开(公告)号： US10603277B2公开(公告)日： 2020-03-31
- 发明人: Ulhas Rameshchandra Dhuppad , Sunil Sudhakar Chaudhari , Suresh Mahadev Rajurkar , Nilesh Jayantilal Jain
- 申请人： GLENMARK PHARMACEUTICALS S.A.
- 申请人地址： CH La Chaux-de-Fonds
- 专利权人： Glenmark Pharmaceuticals S.A.
- 当前专利权人： Glenmark Pharmaceuticals S.A.
- 当前专利权人地址： CH La Chaux-de-Fonds
- 代理机构： Pergament & Cepeda LLP
- 代理商 Milagros A. Cepeda; Edward D. Pergament
- 优先权： IN2090/MUM/2013 20130620
- 主分类号： A61K9/14
- IPC分类号： A61K9/14 ; A61K9/16 ; A61K9/51 ; A61K31/519 ; A61K9/20
摘要：
The present invention relates to a nanoparticulate formulation comprising a transient receptor potential ankyrin-1 receptor (“TRPA1”) antagonist. Particularly, the present invention relates to a nanoparticulate formulation comprising a thienopyrimidinedione derivative as a TRPA1 antagonist and a surface stabilizer; a process for preparing such formulation; and its use in treating a respiratory disorder or pain in a subject.
公开/授权文献
信息查询
